Virtual Library
Start Your Search
Yuriko Terada
Author of
-
+
P3.16 - Surgery (ID 732)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Surgery
- Presentations: 2
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.16-027 - Effects of Surgical Waiting Time on Prognosis in Patients with Lung Cancer (ID 10448)
09:30 - 09:30 | Presenting Author(s): Yuriko Terada
- Abstract
Background:
The effect of surgical waiting time on prognosis in patients with lung cancer remains unknown. The purpose of this study is to examine the impact of surgical waiting time on outcome in patients with lung cancer.
Method:
We retrospectively reviewed all patients who underwent complete surgical resection in a single center between January 2006 and May 2016. Waiting time is defined as the interval between the date of initial visit to the department of respiratory medicine or thoracic surgery and the date of surgery. The patients were divided into two groups based on surgical waiting time: group A (n=160), 0-37 days; group B (n=150), 38 days or longer. Patients who had received neoadjuvant therapy, history of previous primary lung cancer and waiting time greater than 6 months were excluded.
Result:
310 patients met inclusion criteria (65.8% men; median age: 67yrs; c-stage I / II / III 249 / 41 / 20, p-stage I / II / III 212 / 47 / 51, median waiting time: 37 days). Waiting time tends to be shorter as c-stage of disease (I / II / III 38 / 35 / 31.5 days) becomes more advanced. Bronchoscopy or CT guided biopsy before surgery was performed in the group A / B, 160 / 150 patients, respectively. Charlson Comorbidity Index (CCI) (0 / 1 / 2 / 3 / 4 / 5 / 6 / 7) was in the group A: B; 97 / 20 / 33 / 7 / 1 / 0 / 1 / 1: 72 / 27 / 37 / 11 / 2 / 0 / 0 / 1, respectively; group B was significantly associated with higher comorbidity rate. The 5-year RFP in the group A / B was 60.7 / 67.6% (p=0.19) (c-stage I / II / III 70.8 / 31.3 / 21.4%, 68.7 / 66.6 / 50%(p=0.92/0.32/0.3)), respectively. The 5-year OS in the group A / B was 75.6 / 82.6% (p=0.3) (c-stage I / II / III 83.3 / 68 / 21%, 85.7 / 79.3 / 0%(p=0.77 / 0.82 / 0.62)), respectively.
Conclusion:
Surgical waiting time from initial visit to operative intervention does not adversely affect recurrence and survival.
-
+
P3.16-028 - Necrosis Is a Predictor of Recurrence in Patients with Small Lung Adenocarcinoma ≦2cm (ID 10451)
09:30 - 09:30 | Presenting Author(s): Yuriko Terada
- Abstract
Background:
The prognostic significance of pathological necrosis in small lung adenocarcinoma has not been investigated. The purpose of this study is to investigate the prognostic role of pathological necrosis in patients with completely resected small lung adenocarcinoma ≦2cm.
Method:
All available tumor slides from patients with surgically resected lung adenocarcinoma ≦2cm in size (1998-2015) were retrospectively reviewed. Exclusion criteria: patients who received induction therapy and lung cancer surgery within preceding 2 years. Recurrence free probability and overall survival were assessed using the Kaplan-Meier method.
Result:
351 patients met inclusion criteria (48% women, median age 67yr (34-86 yrs), 50% never-smokers; 324 Stage IA, 27 Stage IB; 111 and 240 patients underwent sublobar resection and lobectomy, respectively). Presence of pathological necrosis was identified in 32 patients (9%). Presence of pathological necrosis was significantly associated with sex, smoking, clinical T classification in the 8[th] edition and pathological tumor size (p<0.01, p<0.001, p<0.01, p<0.001, respectively). Presence of pathological necrosis correlated with an increased risk of recurrence, compared with those without pathological necrosis (5-year RFP, 70.5%vs 93.8%; p<0.001). Presence of pathological necrosis did not affect OS (5-year OS, 80.8%vs 92.3%; p=0.21).Figure 1
Conclusion:
In patients with small lung adenocarcinoma ≦2cm, presence of pathological necrosis was significantly associated with increased risk of recurrence.
